Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Official Title

A 6-week, randomized, double-blind, sponsor-open study to assess the effect of repeated subcutaneous administration of pf-06946860 on appetite in participants with advanced cancer and anorexia, followed by an 18-week open-label treatment period

Summary:

Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under the skin) doses.

Trial Description

Primary Outcome:

  • effect of PF 06946860 compared to placebo on appetite
Secondary Outcome:
  • effect of PF 06946860 compared to placebo on appetite
  • effect of PF 06946860 compared to placebo on fatigue
  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
  • Incidence of laboratory abnormalities [Safety and Tolerability]
A 6 week double blind study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated doses injected under the skin (subcutaneously).

During the initial 6-week treatment period (Part A), a total of 2 doses of study drug or placebo will be administered 3 weeks apart. Each dose contains two injections. Part B is an optional 18-week open-label treatment period where up to 7 doses of study drug may be administered. Part B does not include placebo.

Assessments include:
  • Measure the impact of the study drug on appetite, fatigue, and pain questionnaires
  • Body weight measurements
  • Blood samples to evaluate safety and additional endpoints including the amount of the study drug in the blood and the effects of the study drug on levels of a specific cytokine.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society